Serial #98343462
LIVE

Serial Number

98343462

Owner

MagForce NT GmbH

Attorney

Shauna M. Wertheim

Filing Date

Jan 5, 2024

Add to watchlist:

No watchlists yet
View on USPTO

Serial #98343462 Trademark

Serial Number: 98343462

Serial #98343462 is a trademark filed by MagForce NT GmbH on January 5, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

MagForce NT GmbH

Max-Planck-Str. 3
Berlin 12489 , DE

Entity Type: 99

NANOTHERM THERAPEUTICS GMBH

GERHARD-SEDLMAYR-STRAßE 25
BERLIN 12487 , DE

Entity Type: 27

Trademark Details

Filing Date

January 5, 2024

Registration Date

Not Registered

Published for Opposition

September 24, 2024

Goods & Services

Chemical products, namely, magnetic nanoparticles composed of iron oxide for use in industry and scientific research; chemical metallic and magnetic particles and nanometer particles for use in industry and scientific research; chemicals in the nature of biopolymers containing metallic nanoparticles for use in industry and scientific research; synthetic and natural oxides in the form of granules and granulates containing iron oxide in the nature of magnetite and maghemite; chemical products in the form of magnetic nanoparticles, namely, iron oxides in the nature of superparamagnetic nanoparticles and superparamagnetic iron oxide nanoparticles for use in industry and scientific research; chemical preparations in the form of biocompatible polymer nanoparticles, liposomes, coated nanoparticles, and drug-containing nanoparticles, all of the foregoing for use in industry and scientific research, namely, for use in therapy methods, thermotherapy methods, thermoablation methods and/or hyperthermia methods, but not including radiotherapy methods

Medical devices containing magnetic particles, namely, magnetic nanoparticles, superparamagnetic nanoparticles, and nanoparticles containing iron oxide, magnetic powders, granules, and granulates containing iron oxide for providing thermotherapy, thermoablation, hyperthermia for treating malignant or benign tumor diseases, cardiovascular diseases, arthritis, arthrosis, arteriosclerosis, stenosis, restenosis and/or skin diseases, none of the foregoing devices comprising compression equipment systems or apparatus or equipment for radiotherapy

Medical and scientific research in the field of cancer and/or cardiovascular treatment and diagnosis; development and design of medical devices containing magnetic particles, namely, magnetic nanoparticles, superparamagnetic nanoparticles, and nanoparticles containing iron oxide, all for treatment and/or diagnosis of cancer and/or cardiovascular diseases; providing medical testing services and scientific research information in the field of cancer and cardiovascular research; none of the foregoing services comprising radiotherapy in cancer treatment

Diagnostic agents for medical purposes, diagnostic preparations for medical purposes, and pharmaceutical preparations for the treatment of malignant or benign tumor diseases, cardiovascular diseases, arthritis, arthrosis, arteriosclerosis, stenosis, restenosis and/or skin diseases containing magnetic particles, namely, magnetic nanoparticles, superparamagnetic nanoparticles, and nanoparticles comprising iron oxide; pharmaceutical preparations containing metallic or magnetic particles in the nature of nanoparticles for use as anticarcinogenic agents and/or antineoplastic agents, and for treating malignant or benign tumor diseases, cardiovascular diseases, arthritis, arthrosis, arteriosclerosis, stenosis, restenosis and/or skin diseases; contrasting agents for ultrasound diagnostic imaging for medical purposes; none of the foregoing to be used with radiotherapy for cancer treatment

Medical services, namely, medical services in the nature of cancer and cardiovascular therapy, cancer and cardiovascular treatment, and medical diagnosis of cancer and cardiovascular diseases in the nature of dispensing of medical diagnostics and pharmaceutical and medical preparations containing magnetic particles; Physical therapy by conducting medical device-based therapeutic or diagnostic methods, namely, providing physical therapy using magnetic nanoparticles, superparamagnetic nanoparticles, and nanoparticles containing iron oxide; medical services, namely, treatment of malignant or benign tumor diseases, cardiovascular diseases, arthritis, arthrosis, arteriosclerosis, stenosis, restenosis and/or skin diseases; medical services, namely, medical services in the nature of thermotherapeutic services, thermoablation methods and/or hyperthermia methods for cancer and cardiovascular treatment using magnetic nanoparticles, superparamagnetic nanoparticles, and nanoparticles; providing medical testing for diagnostic or treatment purposes in the field of cancer and cardiovascular treatment; none of the foregoing services comprising radiotherapy in cancer treatment

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 7, 2026 EXRA
SOU EXTENSION 3 GRANTED
May 6, 2026 EX3G
SOU EXTENSION 3 FILED
May 6, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
May 6, 2026 EEXT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 8, 2026 ASGN
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 7, 2025 EXRA
SOU EXTENSION 2 GRANTED
Nov 6, 2025 EX2G
SOU EXTENSION 2 FILED
Nov 6, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 6, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 19, 2025 EXRA
SOU EXTENSION 1 GRANTED
May 19, 2025 EX1G
SOU EXTENSION 1 FILED
May 19, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
May 19, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 19, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 24, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 24, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 4, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 16, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 16, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 16, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 16, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 16, 2024 CNEA
ASSIGNED TO EXAMINER
Aug 1, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Apr 22, 2024 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 22, 2024 NWOS
NEW APPLICATION ENTERED
Jan 5, 2024 NWAP